However, some studies have also indicated that autoantibodies to any marker tested were not significantly elevated in patients with severe COVID-19, such as anti-IFN antibodies that are unlikely to promote long-term COVID-19 symptoms after the acute phase of infection [60, 61]. This evidence concerns the gene IFNA1 and infection.